• Molecular NameDarifenacin
  • Synonymdarifenacin
  • Weight426.56
  • Drugbank_IDDB00496
  • ACS_NO133099-04-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.18
  • pkaN/A
  • LogD (pH=7, predicted)2.53
  • Solubility (experiment)6.03 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.61
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds7
  • TPSA55.56
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA medication used to treat urinary incontinence.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability17.0
  • Protein binding98.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2D6- and CYP3A4-mediated)
  • Half life13~19 h
  • ExcretionRenal (60%) and biliary (40%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOverdosage can potentially result in severe central anticholinergic effects.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A